抗菌漱口水预防MSM人群PrEP使用者性传播感染:随机对照交叉试验
在比利时安特卫普单中心开展随机双盲安慰剂对照AB/BA交叉优效性试验,纳入343名使用HIV暴露前预防且近24个月有性传播感染史的MSM,比较每日及性行为前后使用Listerine Cool Mint与安慰剂漱口水各3个月对梅毒、衣原体、淋病联合发病率的影响。
要点
- Listerine漱口水未显著降低MSM人群PrEP使用者的性传播感染联合发病率。
- 研究因COVID-19疫情提前终止,仅151人完成全程、89人完成首3个月。
- 严重不良事件4例均被认为与漱口水使用无关。
核心结论
- 研究结果不支持将Listerine Cool Mint漱口水作为高危人群预防性传播感染的措施。
研究设计与样本
- 单中心、随机、双盲、安慰剂对照、AB/BA交叉优效性试验,在比利时安特卫普热带医学研究所开展。
- 纳入近24个月有性传播感染史且使用HIV暴露前预防的MSM,采用区组随机化(区组大小8)按1:1分配先接受Listerine Cool Mint或安慰剂漱口水。
- 受试者需每日及性行为前后使用研究漱口水各3个月,并要求性伴侣在性行为前后使用漱口水。
- 每3个月筛查口咽、肛门直肠和尿道的梅毒、衣原体和淋病,主要结局为每个3个月期间这些性传播感染的联合发病率,在意向治疗人群中评估。
- 共入组343人,Listerine-安慰剂组172人,安慰剂-Listerine组171人;151人完成全程研究,89人仅完成首3个月。
主要发现
- 不良事件数量与基线相比无显著升高,使用Listerine与安慰剂期间相似。
- 4例严重不良事件(1例HIV感染、1例重度抑郁、1例路德维希咽峡炎、1例睾丸癌)被认为与漱口水使用无关。
临床怎么用
- 临床不应推荐使用Listerine Cool Mint漱口水作为MSM人群PrEP使用者预防性传播感染的干预措施。
局限性
- 试验因COVID-19疫情提前终止,仅151人完成全程研究,样本量受限。
- 31人撤回知情同意,10人失访,1人感染HIV。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bacterial sexually transmitted infections (STIs) are highly prevalent among men who have sex with men who use HIV pre-exposure prophylaxis (PrEP), which leads to antimicrobial consumption linked to the emergence of antimicrobial resistance. We aimed to assess use of an antiseptic mouthwash as an antibiotic sparing approach to prevent STIs. METHODS: We invited people using PrEP who had an STI in the past 24 months to participate in this single-centre, randomised, double-blind, placebo-controlled, AB/BA crossover superiority trial at the Institute of Tropical Medicine in Antwerp, Belgium. Using block randomisation (block size eight), participants were assigned (1:1) to first receive Listerine Cool Mint or a placebo mouthwash. They were required to use the study mouthwashes daily and before and after sex for 3 months each and to ask their sexual partners to use the mouthwash before and after sex. Participants were screened every 3 months for syphilis, chlamydia, and gonorrhoea at the oropharynx, anorectum, and urethra. The primary outcome was combined incidence of these STIs during each 3-month period, assessed in the intention-to-treat population, which included all participants who completed at least the first 3-month period. Safety was assessed as a secondary outcome. This trial is registered with Clinicaltrials.gov, NCT03881007. FINDINGS: Between April 2, 2019, and March 13, 2020, 343 participants were enrolled: 172 in the Listerine followed by placebo (Listerine-placebo) group and 171 in the placebo followed by Listerine (placebo-Listerine) group. The trial was terminated prematurely because of the COVID-19 pandemic. 151 participants completed the entire study, and 89 completed only the first 3-month period. 31 participants withdrew consent, ten were lost to follow-up, and one acquired HIV. In the Listerine-placebo group, the STI incidence rate was 140·4 per 100 person-years during the Listerine period, and 102·6 per 100 person-years during the placebo period. In the placebo-Listerine arm, the STI incidence rate was 133·9 per 100 person-years during the placebo period, and 147·5 per 100 person-years during the Listerine period. We did not find that Listerine significantly reduced STI incidence (IRR 1·17, 95% CI 0·84-1·64). Numbers of adverse events were not significantly higher than at baseline and were similar while using Listerine and placebo. Four serious adverse events (one HIV-infection, one severe depression, one Ludwig's angina, and one testicular carcinoma) were not considered to be related to use of mouthwash. INTERPRETATION: Our findings do not support the use of Listerine Cool Mint as a way to prevent STI acquisition among high-risk populations. FUNDING: Belgian Research Foundation - Flanders (FWO 121·00).
引用
- Van Dijck C, Tsoumanis A, Rotsaert A, et al. Antibacterial mouthwash to prevent sexually transmitted infections in men who have sex with men taking HIV pre-exposure prophylaxis (PReGo): a randomised, placebo-controlled, crossover trial. Lancet Infect Dis. 2021. PMID: 33676596. doi:10.1016/S1473-3099(20)30778-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。